Literature DB >> 12640524

Anti-Saccharomyces cerevisiae antibodies in Japanese patients with inflammatory bowel disease: diagnostic accuracy and clinical value.

Takashi Hisabe1, Toshiyuki Matsui, Toshihiro Sakurai, Yuji Murakami, Hiroshi Tanabe, Hiroaki Matake, Tsuneyoshi Yao, Shino Kamachi, Akinori Iwashita.   

Abstract

BACKGROUND: The diagnostic accuracy of the determination of anti- Saccharomyces cerevisiae antibodies (ASCA) and its clinical significance in Crohn's disease (CD) have been reported in Western countries, but scarcely reported in Japan, where the dietary habits of people differ markedly from those of Western countries. Th present study was undertaken to examine the diagnostic accuracy and clinical significance of ASCA determination in Japanese patients with CD or ulcerative colitis (UC).
METHODS: Seventy-five serum samples obtained from 68 patients with CD, 34 serum samples obtained from 30 patients with UC, 35 serum samples from 35 patients with liver cirrhosis, and 31 serum samples from 31 healthy controls were examined. The optical density of each sample was measured by an enzyme-linked immunosorbent assay (ELISA) method to quantify ASCA IgA and IgG.
RESULTS: The cutoff level, as determined by discriminant analysis of the data, was 0.1502 for ASCA IgA and 0.156 for ASCA IgG. Of the 68 patients with CD, 31 (45.6%) were ASCA-positive, and of the 30 patients with UC, 4 (13.3%) were ASCA-positive according to these cutoff levels. The sensitivity and specificity of ASCA determination for the differential diagnosis of CD from UC were 45.6% and 86.7%, respectively. When the relationship between ASCA and the clinical features of CD was analyzed, ASCA positivity was found to be correlated with duration of illness.
CONCLUSIONS: The specificity of ASCA was high; however, the sensitivity was not. ASCA titers were generally low in the Japanese population examined. It would be desirable to determine cutoff levels for ASCA tailored to the Japanese people for the diagnosis of inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12640524     DOI: 10.1007/s005350300020

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  13 in total

1.  Anti-Saccharomyces cerevisiae antibodies associate with phenotypes and higher risk for surgery in Crohn's disease: a meta-analysis.

Authors:  Zhaoxia Zhang; Chen Li; Xinmei Zhao; Chaolan Lv; Qiong He; Shan Lei; Yandong Guo; Fachao Zhi
Journal:  Dig Dis Sci       Date:  2012-06-06       Impact factor: 3.199

2.  Anti-high mobility group box 1 and box 2 non-histone chromosomal proteins (HMGB1/HMGB2) antibodies and anti-Saccharomyces cerevisiae antibodies (ASCA): accuracy in differentially diagnosing UC and CD and correlation with inflammatory bowel disease phenotype.

Authors:  Hiromasa Takaishi; Takanori Kanai; Atsushi Nakazawa; Fumihiko Sugata; Akira Nikai; Shigeo Yoshizawa; Yasuo Hamamoto; Shinsuke Funakoshi; Tomoharu Yajima; Yasushi Iwao; Masao Takemura; Shoichi Ozaki; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2012-05-30       Impact factor: 7.527

3.  Serological markers (anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic antibodies) in inflammatory bowel disease: diagnostic utility and phenotypic correlation.

Authors:  M S Buckland; M Mylonaki; D Rampton; H J Longhurst
Journal:  Clin Diagn Lab Immunol       Date:  2005-11

4.  Possible diagnostic role of antibodies to Crohn's disease peptide (ACP): results of a multicenter study in a Japanese cohort.

Authors:  Keiichi Mitsuyama; Mikio Niwa; Junya Masuda; Hiroshi Yamasaki; Kotaro Kuwaki; Hidetoshi Takedatsu; Teppei Kobayashi; Fukunori Kinjo; Kazuto Kishimoto; Toshiyuki Matsui; Fumihito Hirai; Kazuya Makiyama; Kazuo Ohba; Hiroo Abe; Hirohito Tsubouchi; Hiroshi Fujita; Ryuichiro Maekawa; Hiroshi Yoshida; Michio Sata
Journal:  J Gastroenterol       Date:  2013-12-03       Impact factor: 7.527

Review 5.  Noninvasive methods in evaluation of inflammatory bowel disease: where do we stand now? An update.

Authors:  Cansel Turkay; Benan Kasapoglu
Journal:  Clinics (Sao Paulo)       Date:  2010-02       Impact factor: 2.365

6.  Inflammatory bowel disease serology in Asia and the West.

Authors:  Lani Prideaux; Michael A Kamm; Peter De Cruz; Daniel R van Langenberg; Siew C Ng; Iris Dotan
Journal:  World J Gastroenterol       Date:  2013-10-07       Impact factor: 5.742

7.  Antibodies to Crohn's disease peptide 353 as a diagnostic marker for pediatric Crohn's disease: a prospective multicenter study in Japan.

Authors:  Tatsuki Mizuochi; Katsuhiro Arai; Takahiro Kudo; Ryusuke Nambu; Hitoshi Tajiri; Tomoki Aomatsu; Naoki Abe; Toshihiko Kakiuchi; Kunio Hashimoto; Tsuyoshi Sogo; Michiko Takahashi; Yuri Etani; Yugo Takaki; Ken-Ichiro Konishi; Jun Ishihara; Hitoshi Obara; Tatsuyuki Kakuma; Shunsuke Kurei; Yushiro Yamashita; Keiichi Mitsuyama
Journal:  J Gastroenterol       Date:  2020-01-24       Impact factor: 7.527

8.  Role of environmental factors in the pathogenesis of Crohn's disease: a critical review.

Authors:  Yueying Chen; Yining Wang; Jun Shen
Journal:  Int J Colorectal Dis       Date:  2019-11-16       Impact factor: 2.571

Review 9.  New serological biomarkers of inflammatory bowel disease.

Authors:  Xuhang Li; Laurie Conklin; Philip Alex
Journal:  World J Gastroenterol       Date:  2008-09-07       Impact factor: 5.742

Review 10.  Antibody markers in the diagnosis of inflammatory bowel disease.

Authors:  Keiichi Mitsuyama; Mikio Niwa; Hidetoshi Takedatsu; Hiroshi Yamasaki; Kotaro Kuwaki; Shinichiro Yoshioka; Ryosuke Yamauchi; Shuhei Fukunaga; Takuji Torimura
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.